Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Good Biotech Corp. is a Taiwan-based biotechnology firm specializing in the development and production of avian-derived Immunoglobulin Y (IgY) antibodies. The company utilizes its proprietary "Functional IgY" technology platform to create high-purity, high-affinity antibodies that serve as alternatives to traditional mammalian antibodies. Their product portfolio primarily targets the diagnostic and therapeutic sectors, with a specific focus on gastrointestinal health and inflammatory markers. Key commercial offerings include IgY-based solutions for neutralizing Helicobacter pylori and high-sensitivity reagents for C-reactive protein (CRP) and Procalcitonin (PCT) assays. Good Biotech also provides customized antibody development and large-scale GMP manufacturing services for global partners in the life sciences industry.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Good Biotech.